Richard F. O'Brien
Boston University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Richard F. O'Brien.
Journal of Cardiovascular Pharmacology | 1992
David M. Rodman; Thomas J. Stelzner; Martin R. Zamora; Scott T. Bonvallet; Masahiko Oka; Katzuhiko Sato; Richard F. O'Brien; Ivan F. McMurtry
Summary: Endothelin-1 (ET-1) is a potent vasoactive peptide that has been reported to cause lung edema. This study tested if the edemagenic effect of ET-1 is due to preferential venoconstriction and, if so, whether the site of resistance is similar with salt solution (PSS) and more physiologic blood perfusate. ET-1 caused concentration-dependent contraction of pulmonary arterial and venous rings, with an EC50 of 1.3 nM in artery and 0.6 nM in vein (p < 0.05). In PSS-perfused lungs, 5 nM ET-1 caused a 7.0 ± 0.8 torr pressor response that was associated with a 5.0 ± 0.3 torr increase in microvascular pressure and a 530 ± 20 mg increase in lung weight within 10 min. In contrast, KCl-treated lungs had an equivalent pressor response (7.4 ±1.1 torr), yet the microvascular pressure increased by only 2.5 ± 0.4 torr (p < 0.05 from ET-1) and the lung weight was unchanged. Meclofenamate did not prevent the effect of ET-1 on microvascular pressure or lung weight. In blood-perfused lungs, ET-1 caused a 7.3 ± 0.1 torr pressor response but only a 2.0 ± 0.5 torr increase in microvascular pressure and no increase in lung weight. ET-1 had no effect on permeability either of cultured endothelial cell monolayers or in the pulmonary microvasculature in vivo. We conclude that the edemagenic effect of ET-1 in PSS-perfused lungs is mediated through venoconstriction and an increase in microvascular pressure. The physiological significance of this increase is uncertain, as blood perfusate appears to shift the principal site of vasoconstriction from post- to precapillary vessels, thus preventing the increase in microvascular pressure and edema.
Experimental Lung Research | 1985
Richard F. O'Brien; Joseph S. Makarski; Sharon Rounds
Lung endothelial cell injury may be an important early event in the pathogenesis of increased permeability pulmonary edema. Since angiotensin converting enzyme (ACE) is located on the luminal surface of the endothelial cell membrane, we sought to determine whether the conversion of angiotensin I (AI) to angiotensin II is decreased after acute lung injury to rats, induced by alpha-naphthylthiourea (ANTU), and we investigated the mechanism of the decrease. We found that lungs isolated from rats treated 4 h earlier with ANTU at a dose of 15 mg/kg body weight (BW) had decreased AI conversion when perfused with Krebs-Henseleit at a constant flow rate of 30 ml/min/kg BW. When perfusate flow rate was increased from 30 to 50 ml/min/kg BW, lungs isolated from rats treated with 10 mg/kg BW ANTU also had decreased AI conversion when compared to controls treated with a vehicle, Tween 80. Investigating the mechanism of decreased AI conversion, there were no differences among experimental groups in pulmonary arterial pressures or effluent perfusate pH or pO2. There was no correlation between lung wet/dry weight ratios and the extent of AI conversion among control rat lungs. Lung homogenate and serum ACE activity did not differ among control rats and rats pretreated with the two doses of ANTU. Ultrastructural studies revealed an increased percentage of capillaries with blebbing of endothelial cells in lungs injured with ANTU, as compared to controls, but no evidence of increased endothelial cell denudation in injured lungs. We conclude that angiotensin I conversion is decreased after ANTU lung injury and that the extent of decrease is related to the dose of ANTU and to perfusate flow rate. Although we cannot exclude decreased vascular surface area perfused as a cause of decreased conversion, we speculate that subtle changes in the luminal endothelial cell membrane may have caused decreased AI conversion after ANTU lung injury.
The American review of respiratory disease | 1990
Richard J. Wallace; Richard F. O'Brien; Jeffrey Glassroth; James W. Raleigh; Asim K. Dutt
The American review of respiratory disease | 1992
Kazuhiko Sato; Sally Webb; Alan Tucker; Marlene Rabinovitch; Richard F. O'Brien; Ivan F. McMurtry; Thomas J. Stelzner
Clinical Infectious Diseases | 1992
Charles L. Shapiro; Rachel F. Haft; Nelson M. Gantz; Gary V. Doern; John C. Christenson; Richard F. O'Brien; James C. Overall; Barbara A. Brown; Richard J. Wallace
The American review of respiratory disease | 1984
Richard F. O'Brien; Margaret P. Seton; Joseph S. Makarski; Sharon Rounds
Chest | 1989
Richard F. O'Brien; Janet L. Quinn; Ben T. Miyahara; Ronald B. Lepoff; David L. Cohn
The American review of respiratory disease | 1989
Richard F. O'Brien
Clinical Infectious Diseases | 1992
Philip C. Hopewell; Michael H. Cynamon; Jeffrey R. Starke; Michael D. Iseman; Richard F. O'Brien
Chest | 1988
Ivan F. McMurtry; David M. Rodman; Takashi Yamaguchi; Richard F. O'Brien